Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)Claudia Marchetti, Riccardo Tudisco, Vanda Salutari, Antonella Pietragalla, Giovanni Scambia, Anna Fagotti
15 June 2021
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)Günter Emons, Jae-Weon Kim, Karin Weide, Nikolaus de Gregorio, Pauline Wimberger, Fabian Trillsch, Boris Gabriel, Dominik Denschlag, Stefan Kommoss, Mustafa Aydogdu, Thomas Papathemelis, Martina Gropp-Meier, Mustafa-Zelal Muallem, Cristin Kühn, Andreas MüllerSee the full list of authors
5 July 2021
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation programEric Lambaudie, Cécile Bannier/Braticevic, Charlène Villaron/Goetgheluck, Christophe Zemmour, Jean-Marie Boher, Patrick Ben Soussan, Jihane Pakradouni, Clement Brun, Leonor Lopez Almeida, Patricia Marino
1 December 2020
Facilitated cascade testing (FaCT): a randomized controlled trialRoni Nitecki, Haley A Moss, Catherine H Watson, Diana L Urbauer, Alexander Melamed, Karen H Lu, Steven M Lipkin, Kenneth Offit, Jose Alejandro Rauh-Hain, Melissa K Frey
18 December 2020
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)Akiko Furusawa, Munetaka Takekuma, Keita Mori, Tomoka Usami, Eiji Kondo, Shin Nishio, Koji Nishino, Yuichiro Miyamoto, Ryoichi Yoshimura, Miho Watanabe, Mikio Mikami, Takayuki Enomoto
4 March 2021
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA TrialAntonio Gonzalez Martin, Luisa Sanchez Lorenzo, Nicoletta Colombo, René dePont Christensen, Florian Heitz, Mihai Meirovitz, Frederic Selle, Toon van Gorp, Nuria Alvarez, Javier Sanchez, Carmen Marqués
14 December 2020
Diagnostic performance of ultrasound in assessing the extension of the disease in patients with suspicion of malignant ovarian tumor: correlation between ultrasound parameters and Fagotti’s scoreMaria Cristina Moruzzi, Giulia Bolomini, Francesca Moro, Floriana Mascilini, Silvia Ficarelli, Giuliana Beneduce, Maria Teresa Giudice, Tina Pasciuto, Rossana Moroni, Giovanni Scambia, Anna Fagotti, Antonia Carla Testa
7 September 2020
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trialFaiza Gaba, Sadiyah Robbani, Naveena Singh, W Glenn McCluggage, Nafisa Wilkinson, Raji Ganesan, Gareth Bryson, Gareth Rowlands, Charlotte Tyson, Rupali Arora, Ertan Saridogan, Helen Hanson, Matthew Burnell, Rosa Legood, D Gareth EvansSee the full list of authors
8 September 2020
Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 studyHua Tu, He Huang, Yi Ouyang, Qing Liu, Bingna Xian, Kun Song, Gang Chen, Yuanming Shen, Jihong Liu
9 June 2020
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, Laura Farrelly, Nicholas Counsell, Amanda Feeney, Fatima El-Khouly, Ian Macdonald, Andreia Neto, Esther Arthur-Darkwa, Eva Burnett, Gordon C Jayson, Linda Mileshkin, Charlie Gourley, Shibani Nicum
23 October 2020